PRGO Div & Yield: 0.20 (0.50%)
P/E (ttm): 35.56
PERIOD ENDING ....29-Dec-07. 29-Sep-07 .30-Jun-07. 31-Mar-07
Retained Earnings .231,850 .. 202,245 .. 178,374 . .163,798 <----
Total Revenue .....435,483 . 382,740 . 374,296 . 362,288 <----
Sale (Buy) Stock. (19,263)......(125) ....8,470 .. (3,725) <-------
Net Borrowings ....(4,740)... (8,099)... (52,002) ...40,406 <-----
http://stockcharts.com/charts/gallery.html?prgo
<--{impressive! needs
retrace to $24]
Qtrly Revenue Growth (yoy): 17.50% <-------good
Qtrly Earnings Growth (yoy): 62.60% <-------xlnt
Total Debt (mrq): 668.55M <----43% of revenue....bzzzt
Perrigo Company, through its subsidiaries, develops, manufactures, and
distributes over-the-counter and prescription pharmaceuticals,
nutritional products, active pharmaceutical ingredients, and consumer
products worldwide. The company operates in three segments: Consumer
Healthcare, Prescription (Rx) Pharmaceuticals, and Active Pharmaceutical
Ingredients (API). The Consumer Healthcare segment offers over-the-
counter pharmaceutical and nutritional products, which include analgesic,
cough/cold/allergy/sinus, gastrointestinal, smoking cessation, first aid,
vitamin and nutritional supplement products primarily in the United
States, the United Kingdom, and Mexico. The Prescription (Rx)
Pharmaceuticals segment develops, manufactures, and markets topical
generic prescription drug products, including creams, ointments, lotions,
gels, shampoos, suppositories, liquid suspensions, and solutions, as well
as nasal sprays, oral liquids, foams, otics, and transdermal products
primarily for the U.S. markets. The API segment engages in the
development, manufacture, and marketing of APIs used by the generic drug
industry and branded pharmaceutical companies primarily in Israel and
Germany. The company also offers consumer products, such as cosmetics,
toiletries, bar soaps, and detergents; manufactures and markets branded
prescription drugs; and im****ts pharmaceutical, diagnostics, and other
medical products. Its customers primarily include retail drug,
supermarket, wholesalers, and mass merchandise chains. The company was
founded in 1887 and is based in Allegan, Michigan.
----------
NEWS ITEM
http://biz.yahoo.com/prnews/080320/clth070.html?.v=101
United States District Court for the District of New Jersey has denied
Connetics Cor****ation's motion for a preliminary injunction related to
Perrigo's Clobetasol Propionate Foam, the AB-rated generic equivalent to
Connetics' Olux® Foam .....As the first filer, this commences its 180
days of generic exclusivity.
...... Sales for the brand, Olux® Foam, 0.05%, were approximately $85
million
The Court also denied Perrigo's motion for Summary Judgment based on non-
infringement. The case will now proceed to trial with the trial date not
having been set.
-----------
Tuesday March 25, 6:07 pm ET
Perrigo Director Gibbons Sells 26,600 Shares for $37.38 to $37.84 apiece.
Tuesday March 11, 11:52 am ET
Perrigo Director David T. Gibbons Sells 45,028 Shares of Common Stock he
exercised the options Thursday for $13.90 apiece and then sold the shares
on the same day for $32.29 to $33.51 apiece
--------
Tuesday March 4, 1:43 pm ET
Perrigo Executive Vice President Refael Lebel Sells 10,605 Shares of
Common Stock he sold the shares Thursday for $34.30 apiece.
---------
Mar. 6 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE)
today announced that its partner, Teva Pharmaceutical Industries Ltd.
(Nasdaq: TEVA - News), has received final approval from the U.S. Food and
Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA)
for over-the-counter Cetirizine Hydrochloride, Pseudoephedrine
Hydrochloride Extended-Release Tablets, 5 mg/120 mg.The product will be
marketed by Perrigo under store brand labels and is comparable to McNeil
Consumer Healthcare's recently launched Zyrtec-D® Extended-Release
Tablets, indicated for 12 hour relief
sales for the original prescription strength version of the product for
the 12 months ending December 2007 were approximately $190 million.
The Company expects to begin ****pping the product in the next 90 days.
---------
March 4 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE)
today announced that it has begun ****pping 20 mg Omeprazole delayed
released tablets to its retail customers. This product delivers the same
medicine at the same dose as Prilosec OTC®. "This is the largest launch
in our 120 year history. The launch of this store brand product will
potentially save consumers more than $100 million per year compared to
the national brand.
|
